NCT00976326View on ClinicalTrials.gov

A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
DiabetesHealthy
Interventions
DRUG

insulin degludec

The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)

Trial Locations (1)

833 05

Novo Nordisk Investigational Site, Bratislava

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00976326 - A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function | Biotech Hunter | Biotech Hunter